Xenon Pharmaceuticals Inc...

38.00
0.41 (1.09%)
At close: Apr 24, 2025, 2:51 PM
1.09%
Bid 37.98
Market Cap 2.91B
Revenue (ttm) n/a
Net Income (ttm) -234.33M
EPS (ttm) -3.01
PE Ratio (ttm) -12.62
Forward PE -8.14
Analyst Buy
Ask 38.03
Volume 418,741
Avg. Volume (20D) 621,085
Open 37.49
Previous Close 37.59
Day's Range 37.22 - 38.05
52-Week Range 26.74 - 46.00
Beta 1.22

About XENE

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment o...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 5, 2014
Employees 316
Stock Exchange NASDAQ
Ticker Symbol XENE
Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for XENE stock is "Buy." The 12-month stock price forecast is $55, which is an increase of 44.74% from the latest price.

Stock Forecasts